Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Solid Tumors × dalotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 3 Colorectal Neoplasms 2 Breast Neoplasms 2 Solid Tumors 1 Ovarian Neoplasms 1 Multiple Myeloma 1 Fallopian Tube Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Solid Tumors 1

Interventions

Injections 15 Carboplatin 14 Docetaxel 10 pembrolizumab 7 durvalumab 6 Cisplatin 6 linifanib 5 Paclitaxel 5 talazoparib 4 olaparib 4 Panobinostat 4 Nivolumab 4 Itraconazole 4 Bevacizumab 4 zimberelimab 3 sintilimab 3 depatuxizumab 3 atezolizumab 3 ST 1481 3 S 1 (combination) 3 Rifampin 3 Pemetrexed 3 Fluorouracil 3 trifluridine tipiracil drug combination 2 tremelimumab 2 tislelizumab 2 tesetaxel 2 spartalizumab 2 motesanib diphosphate 2 ixabepilone 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00635778 2018-10-09

MK-0646-002

Merck Sharp & Dohme LLC

Phase 1 Completed

50 enrolled 32 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡